Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ORKABullishResearch Analysisnews

High materiality8/10

Oruka's ORKA-001 Shows Durable Psoriasis Efficacy; Long-Term Data Ahead in 2026

Sep 23, 2026, 10:42 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong week-28 efficacy signals and durability potential improve the case for durable approval-agnostic value, especially with December 2026 readouts and Q4 2026 data still ahead; catalysts could drive multiple expansion if results persist.

AI summary

What happened, with direct paths to the underlying reporting

Oruka Therapeutics reported week 28 data from the Phase 2a ORKA-001 psoriasis trial, showing sustained activity with 71.4% achieving PASI 100 and 87.3% attaining PASI 90. The safety profile remains favorable, with no injection-site reactions and only two serious adverse events deemed unrelated. Key upcoming readouts—EVERLAST-A at 52 weeks (Dec 2026) and EVERLAST-B data in Q4 2026—could meaningfully influence ORKA's valuation if durability holds.

Week 28 results show deepening ORKA-001 efficacy in psoriasis.
PASI 100 at 71.4% and PASI 90 at 87.3% by week 28.
Safety profile remains favorable with no injection-site reactions.
Long-term data due December 2026; 2H26 readouts for EVERLAST-B in Q4 2026.
Stock action modestly lower; data catalysts could re-rate valuation.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.